The Bangladesh Medical and Research Council (BMRC) has finally approved the clinical trials of Covaxin in Bangladesh. BMRC Chairman Prof Dr. Syed Modasser Ali has confirmed the approval of the trials. The Contract Research Organization (CRO) had applied for permission for the clinical trials of the Indian vaccine in Bangladesh a few months ago.
Prof Dr. Syed Modasser Ali informed that an independent committee was formed to review the vaccine, and after a full scientific analysis, the human trial was permitted.
The coronavirus has affected the whole world and the vaccines have played a significant role in reducing the effect of the deadly virus. India has constantly extended help to other nations in difficult times by providing life-saving medical aids.
The Bangladesh Medical Research Council (BMRC) approved the trials of Covaxin in the country on July 18. The clinical trials of the vaccine got approval from the Bangladesh Medical and Research Council after reviewing the necessary documents related to the permission. Covaxin has been jointly developed by Bharat Biotech and the Indian Council of Medical Research (ICMR). The approval of the clinical trials will strengthen India’s indigenous vaccine recognition across the globe.
Phase 3 clinical trial of COVAXIN showed 81% efficacy in India
The trials were conducted on 25,800 individuals across 21 sites. The interim efficacy trend was around 81% which was analyzed as per the protocol approved by the DCGI. The result of Covaxin was at par with other global front-runner vaccines.
COVAXIN has been developed on the WHO pre-qualified Vero cell platform, which is globally recognized with a well-established track record of safety.